HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy
and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma
(AA).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System